GO:0048002 antigen processing and presentation of peptide antigen: Immune Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048002 describes the biological process in which an antigen-presenting cell expresses peptide antigen in association with an MHC protein complex on its cell surface, including proteolysis and transport steps before and after MHC assembly.
• The pathway is divided into MHC class I and MHC class II routes, which differ in peptide source, proteolytic machinery, and intracellular trafficking.
• MHC class I presents mainly endogenous peptides to CD8+ T cells, while MHC class II presents mainly exogenous peptides to CD4+ T cells.
• Cross-presentation allows exogenous antigens to be presented on MHC class I, a process critical for immunity to tumors and viruses.
• Interferon-gamma upregulates multiple components of the MHC class I antigen processing and presentation machinery.
• Computational tools such as MHCflurry 2.0 incorporate antigen processing features to improve prediction of MHC class I-presented peptides.
Description
Antigen processing and presentation of peptide antigen (GO:0048002) is the biological process by which an antigen-presenting cell expresses peptide antigen in association with an MHC protein complex on its cell surface, including proteolysis and transport steps for the peptide antigen both prior to and following assembly with the MHC protein complex. This process is central to adaptive immunity because it converts intracellular and extracellular proteins into short peptides that can be recognized by T cells. The pathway is traditionally divided into MHC class I and MHC class II presentation, which survey different protein pools and engage distinct proteolytic and trafficking machineries. Researchers study GO:0048002 to understand how immune surveillance detects infected or transformed cells, how tolerance is maintained, and how antigen presentation shapes vaccine responses and immunotherapy outcomes. The process also has broad relevance beyond classical immunology, including autoimmunity, transplant rejection, and cancer immunoediting. Because peptide-MHC complexes are the molecular targets of T cell receptors, accurate mapping of antigen processing and presentation is essential for epitope discovery and T cell-based therapeutics. Recent reviews emphasize that antigen processing and presentation is not a single linear route but a dynamic network of proteolytic events, chaperone-assisted peptide loading, and vesicular transport steps that can be modulated by cytokines and cellular stress. This complexity makes the pathway a rich area for functional genomics and CRISPR-based perturbation studies.
antigen processing and presentation of peptide antigen At A Glance
| GO ID | GO:0048002 |
|---|---|
| GO term | antigen processing and presentation of peptide antigen |
| Ontology | biological_process |
| Synonym | antigen presentation, peptide antigen; peptide antigen processing and presentation |
| Major function | Generation and cell-surface display of peptide-MHC complexes for T cell recognition |
| Peptide source | Typically endogenous or exogenous proteins, but not always |
| Key cellular compartments | Cytosol, proteasome, ER, endosomes, lysosomes, plasma membrane |
| Major MHC classes | MHC class I and MHC class II |
| Representative cytokines | Interferon-gamma upregulates MHC class I pathway components |
What Is GO:0048002?
GO:0048002, antigen processing and presentation of peptide antigen, is defined as the process in which an antigen-presenting cell expresses peptide antigen in association with an MHC protein complex on its cell surface, including proteolysis and transport steps for the peptide antigen both prior to and following assembly with the MHC protein complex; the peptide antigen is typically, but not always, processed from an endogenous or exogenous protein. In other words, it covers the entire journey from protein substrate to surface-displayed peptide-MHC complex, including degradation, peptide trimming, transport, MHC loading, and surface presentation.
Why Is antigen processing and presentation of peptide antigen Important in Cell Biology?
GO:0048002 is important because peptide-MHC complexes are the central molecular readout of adaptive immunity, and their generation determines whether T cells mount protective responses against pathogens and tumors or instead drive autoimmunity and transplant rejection. Defects in antigen processing and presentation can lead to immune evasion by cancer cells and impaired pathogen clearance, while overactivation can contribute to autoimmune pathology. Understanding this process at mechanistic resolution is therefore essential for vaccine design, checkpoint immunotherapy, and T cell engineering.
• Defines the molecular basis of T cell recognition through peptide-MHC complexes.
• MHC class I presentation enables CD8+ T cell surveillance of intracellular pathogens and tumors.
• MHC class II presentation enables CD4+ T cell help and shaping of humoral immunity.
• Cross-presentation links exogenous antigens to MHC class I and is critical for antitumor immunity.
• Interferon-gamma upregulates MHC class I antigen processing and presentation components.
• Antigen processing features improve computational prediction of MHC class I epitopes.
• Dysregulation contributes to cancer immune evasion and autoimmune disease.
• HLA-DP antigen processing and presentation has distinct mechanistic features relevant to disease association.
• Dynamic trafficking of MHC-I molecules regulates the antigen processing and presentation pathway.
• The pathway is a major target for therapeutic modulation in immunotherapy and vaccinology.
What Happens During antigen processing and presentation of peptide antigen?
MHC class I pathway: proteasomal degradation and peptide transport
In simple terms: In the MHC class I route, proteins inside the cell are chopped into peptides and moved into the endoplasmic reticulum for loading onto MHC class I.
The MHC class I pathway begins with cytosolic or nuclear proteins that are targeted for degradation, often by the ubiquitin-proteasome system, generating short peptide fragments. These peptides are transported into the endoplasmic reticulum by the transporter associated with antigen processing (TAP), where they are further trimmed and loaded onto MHC class I molecules. Interferon-gamma upregulates multiple components of this pathway, including proteasome subunits and TAP, thereby enhancing peptide supply for MHC class I presentation. The peptide-MHC class I complex then traffics through the secretory pathway to the cell surface for recognition by CD8+ T cells.
MHC class II pathway: endosomal processing and peptide loading
In simple terms: In the MHC class II route, proteins taken up from outside the cell are digested in endosomes and loaded onto MHC class II for display to CD4+ T cells.
The MHC class II pathway processes exogenous antigens that are internalized into endosomes and lysosomes, where proteases degrade them into peptides. MHC class II molecules are synthesized in the endoplasmic reticulum with the invariant chain, which blocks the peptide-binding groove and directs trafficking to endosomal compartments. In these compartments, the invariant chain is progressively degraded, and the remaining CLIP fragment is exchanged for high-affinity peptides, a step catalyzed by HLA-DM. The resulting peptide-MHC class II complexes are then transported to the plasma membrane for presentation to CD4+ T cells.
Cross-presentation: exogenous antigens on MHC class I
In simple terms: Cross-presentation is a special route where antigens from outside the cell are presented on MHC class I, allowing CD8+ T cells to see external threats.
Cross-presentation allows exogenous antigens to be processed and presented on MHC class I molecules, a process particularly important for immunity to tumors and viruses that do not infect antigen-presenting cells directly. Mechanistically, cross-presentation can involve cytosolic routing of internalized antigens for proteasomal degradation and TAP-dependent loading onto MHC class I, or vacuolar pathways where peptides are loaded onto MHC class I within endosomal compartments. This pathway is critical for priming CD8+ T cell responses and is a major focus of vaccine and immunotherapy research.
Peptide trimming and MHC loading
In simple terms: Peptides often need to be trimmed to the right length before they can sit stably in the MHC groove.
Peptide trimming is essential for generating optimal MHC ligands. In the MHC class I pathway, aminopeptidases such as ERAP1 trim peptides in the endoplasmic reticulum, while in the MHC class II pathway, cathepsins and other proteases generate peptides in endosomes. The loading of peptide onto MHC is assisted by chaperones and accessory molecules, including tapasin for MHC class I and HLA-DM for MHC class II. The stability and surface lifetime of peptide-MHC complexes depend on peptide affinity and on dynamic trafficking of MHC molecules.
Surface presentation and T cell recognition
In simple terms: Once peptide-MHC complexes reach the cell surface, they can be recognized by T cell receptors, triggering immune responses.
After assembly, peptide-MHC complexes are transported to the plasma membrane, where they can engage T cell receptors on CD8+ or CD4+ T cells. The density and quality of surface peptide-MHC complexes determine the strength of T cell activation and shape downstream immune responses. Dynamic imaging and biochemical studies have revealed that MHC-I molecules traffic through distinct intracellular pools and that their surface dynamics influence antigen presentation efficiency. Computational models that incorporate antigen processing features can predict which peptides are likely to be presented, aiding epitope discovery.
Key Genes Involved in GO:0048002 antigen processing and presentation of peptide antigen
The following genes and proteins are core components of antigen processing and presentation of peptide antigen (GO:0048002), spanning proteolysis, transport, MHC loading, and surface presentation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HLA-A | MHC class I heavy chain; presents endogenous peptides to CD8+ T cells | Target for KO and epitope discovery studies |
| HLA-B | MHC class I heavy chain; presents endogenous peptides | Commonly studied in cancer immunology and transplantation |
| HLA-C | MHC class I heavy chain; presents peptides and interacts with NK cells | Relevant to NK cell regulation and immune evasion |
| B2M | Beta-2-microglobulin; essential light chain of MHC class I | Frequent KO target to abolish MHC class I surface expression |
| TAP1 | Transporter associated with antigen processing; moves peptides into ER | KO models used to study peptide supply defects |
| TAP2 | Transporter associated with antigen processing; forms TAP complex with TAP1 | Target for functional studies of peptide transport |
| PSMB8 | Immunoproteasome subunit; generates peptides for MHC class I | Interferon-inducible; studied in inflammation and cancer |
| PSMB9 | Immunoproteasome subunit; generates peptides for MHC class I | KO models reveal altered peptide repertoires |
| ERAP1 | Aminopeptidase; trims peptides for MHC class I loading | Associated with autoimmunity; KO models study peptide trimming |
| ERAP2 | Aminopeptidase; trims peptides for MHC class I loading | Studied in combination with ERAP1 for peptide repertoire |
| HLA-DRA | MHC class II alpha chain; presents exogenous peptides to CD4+ T cells | Target for KO in CD4+ T cell studies |
| HLA-DRB1 | MHC class II beta chain; presents exogenous peptides | Strong disease associations; knock-in models for risk alleles |
| HLA-DPA1 | MHC class II alpha chain for HLA-DP | Studied in HLA-DP antigen processing |
| HLA-DPB1 | MHC class II beta chain for HLA-DP | Mechanistic studies of HLA-DP presentation |
| CD74 | Invariant chain; blocks MHC class II groove and directs trafficking | KO models show altered MHC class II peptide loading |
| HLA-DM | Catalyzes peptide exchange on MHC class II | KO models reveal CLIP accumulation and peptide editing defects |
| CTSS | Cathepsin S; degrades invariant chain in endosomes | KO models study MHC class II processing |
| LAMP2A | Chaperone-mediated autophagy receptor; can influence antigen processing | Studied in cross-presentation and autophagy |
| CANX | Calnexin; chaperone for MHC class I assembly | KO models study MHC class I folding and quality control |
How Is antigen processing and presentation of peptide antigen Regulated?
Antigen processing and presentation of peptide antigen is regulated at multiple levels, including cytokine signaling, transcriptional control, and vesicular trafficking. Interferon-gamma upregulates many components of the MHC class I pathway, such as proteasome subunits, TAP, and MHC class I itself, thereby increasing peptide supply and surface presentation. MHC class II expression is controlled by the master transcription factor CIITA in response to inflammatory signals, and peptide loading is regulated by HLA-DM and invariant chain processing. Dynamic trafficking of MHC-I molecules through intracellular compartments also modulates the efficiency of antigen presentation. In addition, cross-presentation pathways are regulated by endosomal pH, reactive oxygen species, and autophagy-related processes.
antigen processing and presentation of peptide antigen and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| B2M | Cancer immune evasion; loss causes MHC class I deficiency | B2M knockout tumor cell lines |
| HLA-DRB1 | Autoimmune disease associations | HLA-DRB1 knock-in mice or cell lines |
| ERAP1 | Autoimmunity and altered peptide trimming | ERAP1 knockout or point-mutation cell models |
| TAP1 | Impaired peptide transport and immunodeficiency | TAP1 knockout cell lines |
| HLA-DPB1 | HLA-DP-associated disease risk | HLA-DPB1 knock-in or overexpression models |
Cancer immune evasion
Tumors frequently evade immune detection by disrupting antigen processing and presentation, for example through loss of B2M or MHC class I expression, which prevents CD8+ T cell recognition. Defects in the MHC class I pathway can also reduce responsiveness to checkpoint immunotherapy. Understanding these mechanisms is critical for developing strategies to restore antigen presentation in tumors.
Autoimmune and inflammatory diseases
Altered antigen processing and presentation can contribute to autoimmunity by displaying self-peptides that activate autoreactive T cells. Polymorphisms in MHC class II genes, particularly HLA-DR and HLA-DP, are strongly associated with autoimmune conditions, and mechanistic studies of HLA-DP antigen processing have refined our understanding of these associations. ERAP1 variants that affect peptide trimming have also been linked to autoimmune risk.
Infectious disease and vaccine responses
Effective presentation of pathogen-derived peptides is essential for protective immunity, and many pathogens evolve mechanisms to interfere with MHC class I or class II pathways. Cross-presentation is particularly important for vaccines that aim to elicit CD8+ T cell responses against viruses and intracellular bacteria. Understanding antigen processing can guide vaccine antigen selection and delivery strategies.
From antigen processing and presentation of peptide antigen-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene abolish MHC class I surface presentation? | Knockout cell line (e.g., B2M, TAP1) |
| Does a disease-associated SNP alter peptide loading? | Point-mutation knock-in cell line |
| Can a specific HLA allele present a defined epitope? | HLA knock-in or overexpression cell model |
| Where does a protein localize during antigen processing? | Tagged knock-in (e.g., GFP or HA tag) |
| Does overexpression of a protease enhance cross-presentation? | Overexpression cell model |
| Which genes regulate antigen presentation in a genome-wide screen? | CRISPR library screening |
How to Study the antigen processing and presentation of peptide antigen Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Immunopeptidomics | Peptide sequences eluted from MHC molecules | Discovering presented epitopes |
| Flow cytometry | Surface MHC class I/II levels | Validating antigen presentation defects |
| CRISPR knockout screens | Genes required for antigen presentation | Identifying regulatory networks |
| RNA-seq | Expression of antigen processing genes | Assessing transcriptional regulation |
| Proteomics | Protein abundance of MHC pathway components | Quantifying pathway remodeling |
| Confocal microscopy | Intracellular trafficking of MHC molecules | Studying vesicular transport |
| MHC binding prediction | Predicted peptide-MHC affinity | Epitope prioritization |
Immunopeptidomics and mass spectrometry
Immunopeptidomics uses mass spectrometry to identify peptides eluted from MHC molecules, providing a direct readout of the antigen processing and presentation pathway. This method can reveal peptide repertoires associated with specific HLA alleles and how they change upon genetic perturbation.
Flow cytometry and surface MHC staining
Flow cytometry with antibodies against MHC class I or class II can quantify surface presentation and assess how knockout or knock-in of candidate genes affects peptide-MHC levels. This approach is widely used to validate antigen processing defects in cell models.
CRISPR screens and functional genomics
Genome-wide CRISPR screens can identify genes that regulate antigen presentation, for example by selecting for cells with altered MHC surface levels or resistance to T cell killing. These screens provide unbiased insights into the genetic network controlling GO:0048002.
Computational prediction of peptide-MHC binding
Computational tools such as MHCflurry 2.0 incorporate antigen processing features to predict which peptides are likely to be presented by MHC class I. These models are valuable for prioritizing epitopes for experimental validation.
How CRISPR Can Be Used to Study GO:0048002 antigen processing and presentation of peptide antigen
Knockout
CRISPR knockout of genes such as B2M, TAP1, or HLA-DM can abolish or impair specific antigen presentation routes, providing clean models to study GO:0048002. These models are widely used to dissect the contribution of individual components to peptide-MHC surface levels.
Point Mutation
Point mutations can be introduced to model disease-associated variants, such as ERAP1 polymorphisms or HLA alleles, and to test their impact on peptide trimming and presentation. These models help link genetic variation to functional changes in antigen processing.
Knock-in
Knock-in of specific HLA alleles or tagged MHC molecules allows researchers to track presentation of defined epitopes and to study allele-specific peptide repertoires. Tagged knock-ins enable imaging and biochemical isolation of peptide-MHC complexes.
Overexpression
Overexpression of antigen processing components, such as immunoproteasome subunits or cathepsins, can enhance or alter peptide generation and presentation. These models are useful for testing whether increasing pathway activity boosts T cell recognition.
How EDITGENE Supports antigen processing and presentation of peptide antigen Research
Researchers studying antigen processing and presentation of peptide antigen-related genes often need to determine whether a candidate gene is causally involved in peptide-MHC presentation, whether a disease-associated variant alters peptide loading, or whether overexpression enhances T cell recognition. EDITGENE provides CRISPR-based cell model services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for antigen processing and presentation of peptide antigen research.
Frequently Asked Questions About antigen processing and presentation of peptide antigen
What is GO:0048002?
GO:0048002 is the biological process in which an antigen-presenting cell expresses peptide antigen in association with an MHC protein complex on its cell surface, including proteolysis and transport steps before and after MHC assembly.
What is antigen processing and presentation of peptide antigen?
It is the pathway that converts proteins into peptides and displays them on MHC molecules for T cell recognition, covering both MHC class I and class II routes.
What genes are involved in antigen processing and presentation of peptide antigen?
Key genes include HLA-A, HLA-B, HLA-C, B2M, TAP1, TAP2, PSMB8, PSMB9, ERAP1, ERAP2, HLA-DRA, HLA-DRB1, CD74, and HLA-DM.
How does MHC class I antigen presentation work?
Cytosolic proteins are degraded by the proteasome, peptides are transported by TAP into the ER, loaded onto MHC class I, and then displayed on the cell surface for CD8+ T cells.
How does MHC class II antigen presentation work?
Exogenous antigens are internalized and degraded in endosomes, and peptides are loaded onto MHC class II with the help of HLA-DM before surface presentation to CD4+ T cells.
What is cross-presentation?
Cross-presentation is the process by which exogenous antigens are presented on MHC class I molecules, enabling CD8+ T cell responses to tumors and viruses.
How is antigen processing and presentation regulated?
It is regulated by cytokines such as interferon-gamma, transcription factors like CIITA, and vesicular trafficking, which together control peptide supply and surface presentation.
Why is antigen processing and presentation important in cancer?
Tumors can evade immunity by disrupting this pathway, and defects in MHC class I presentation reduce T cell recognition and immunotherapy responses.
What methods are used to study antigen processing and presentation?
Common methods include immunopeptidomics, flow cytometry, CRISPR screens, RNA-seq, proteomics, and computational MHC binding prediction.
How can CRISPR help study antigen processing and presentation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of gene function in the pathway, while CRISPR screens identify novel regulators.
Conclusion
GO:0048002, antigen processing and presentation of peptide antigen, is a central biological process that converts proteins into peptide-MHC complexes for T cell recognition. It encompasses MHC class I and class II pathways, cross-presentation, peptide trimming, and dynamic trafficking, with broad implications for cancer, autoimmunity, and infectious disease. Continued research using CRISPR models and immunopeptidomics will refine our understanding of this pathway and support the development of next-generation immunotherapies.
References
- 1. Pishesha N et al.. 2022. A guide to antigen processing and presentation.. Nat Rev Immunol 22(12):751-764 PMID: 35418563
- 2. Roche PA et al.. 2015. The ins and outs of MHC class II-mediated antigen processing and presentation.. Nat Rev Immunol 15(4):203-16 PMID: 25720354
- 3. Zhou F. 2009. Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation.. Int Rev Immunol 28(3-4):239-60 PMID: 19811323
- 4. Neefjes J et al.. 2011. Towards a systems understanding of MHC class I and MHC class II antigen presentation.. Nat Rev Immunol 11(12):823-36 PMID: 22076556
- 5. O'Donnell TJ et al.. 2020. MHCflurry 2.0: Improved Pan-Allele Prediction of MHC Class I-Presented Peptides by Incorporating Antigen Processing.. Cell Syst 11(1):42-48.e7 PMID: 32711842
- 6. Blander JM et al.. 2023. The show and tell of cross-presentation.. Adv Immunol 159:33-114 PMID: 37996207
- 7. Truong HV et al.. 2021. Dynamics of MHC-I molecules in the antigen processing and presentation pathway.. Curr Opin Immunol 70:122-128 PMID: 34153556
- 8. Anczurowski M et al.. 2018. Mechanisms of HLA-DP Antigen Processing and Presentation Revisited.. Trends Immunol 39(12):960-964 PMID: 30416081
